Nom d'utilisateur :  Mot de Passe :
General information   
Board of directors and founders of Gercor
Legal information
Our partners
The Gercor team
Contact us

 
 
  Cancer needs to be conquered  
  Message from the Chairman  
  A network of physicians  
  Our mission  
  Initial results  
  Ethics and transparency  
  Partners  
  Publications  
 

Initial results :
Treatments are more effective and better tolerated by patients

24 PROTOCOLS APPROVED
• Gercor has undertaken 5 phase III studies into colorectal cancer:
- 3 adjuvant studies:

• C96-1 (905 patients included),
• CPT-V 307 (207 patients included),
• MOSAIC (2200 patients included,
450 of which in France): less toxicity in innovative treatment and an increased PFS have been shown
- 2 studies in metastatic situation
• FOLFOX-FOLFIRI vs FOLFIRIFOLFOX/C97-3 (226 patients included),
• OPTIMOX, therapeutic strategy’s trial in metastatic colorectal cancer (623 patients included).
• Gercor has undertaken 1 phase III study into pancreatic cancer :
GEM-GEMOX (326 patients included).
• Gercor has undertaken 1 phase III study into lung cancer : BOO 1 (74 patients included).
• Gercor has participated in 1 BCIRG phase III study in breast cancer :
BCIRG 005 (37 patients included).
• Gercor has conducted 15 phase II
studies:

- 4 studies on colorectal cancer
- 4 studies on pancreatic cancer
- 1 study on lung cancer
- 2 studies on breast cancer
- 1 study on oesophagus cancer
- 1 study on prostate cancer
- 1 study on bladder cancer
- 1 study on stomach cancer

A longer life expectancy
A better quality of life during the illness
Less toxicity or side effects from treatment

12 PROTOCOLS IN PROGRESS,
• Gercor is participating in 4 phase III
trials

- OPTIMOX 2 CO2-2 (colorectal cancer)
- MIROX (colorectal cancer)
- AERO R98 (rectal cancer)
- BCIRG 006 (breast cancer)

• In addition, Gercor is conducting 8 phase II trials in various cancers including 4 in digestive cancers:
- 1 in oesophageal cancer,
- 2 in pancreatic cancer,
- 3 in lung cancer,
- 1 in ovarian cancer,
- 1 in all cancers.

12 PROTOCOLS IN PREPARATION
• 3 phase III protocols and 9 phase II protocole are currently in preparation, treating:
- colon: 4
- stomach: 3
- breast: 1
- pancreas: 1
- mesothelioma: 1
- lung: 1
- thrombosis prevention: 1

 

 

 

 

 
   
   

 

 

 

 

 

Sitemap